Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer

BACKGROUND: -mutant NSCLC have not been investigated extensively. Observed toxic effects were generally consistent with those in previously reported studies.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 METHODS: -mutant NSCLC that was refractory to standard treatment.
• 2 The primary outcome was objective response as assessed by independent central review.
• 3 Secondary outcomes included the duration of response, progression-free survival, overall survival, and safety.

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: